Tetanus Toxoid
Phase 2Biologic
Tetanus Toxoid is one of 81 biologic programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.
2
Indications
9
Total Trials
1
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
698 competitors in Metastatic Colorectal Cancer
#DrugCompanyPhaseTrials
1SU5416
PfizerPhase 3
Legalon
BBukwang Pharmaceutical
Phase 3
AK112
SSummit Therapeutics
Phase 3
Investigator's Choice Chemotherapy
GenmabPhase 3
QL1706
Qilu Pharmaceutical Co., Ltd.Phase 3
Leucovorin /m^2
RochePhase 3
Eylea
RegeneronPreclinical
Mfolfoxiri Plus Bevacizumab
FFudan University
Phase 3
L-Folinic Acid
IInstitut Cancerologie de l'Ouest
Phase 3
Calmangafodipir
EEgetis Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Antibiotic1 trial
Routine Antibiotic vs. Directed Antibiotic Treatment in Snake Bite
Terminated·JJawaharlal Institute of Postgraduate Medical Education & Research·Phase 4·NCT02570347·66 enrolled
Glioblastoma Multiforme1 trial
Adult1 trial
Immunogenicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tetanus Toxoid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details